Silence Therapeutics plc is a leading biotechnology company that specializes in the development of RNA interference (RNAi) therapeutics. The company was founded in 2002 and is headquartered in London, England. Silence Therapeutics is dedicated to discovering and developing innovative therapies that can treat a wide range of diseases. Its proprietary platform technology allows for the design of highly specific RNAi molecules that can silence disease-causing genes. The company’s pipeline includes several promising drug candidates for the treatment of cardiovascular, metabolic, and oncological diseases. Silence Therapeutics is committed to improving patient outcomes through the development of safe and effective RNAi therapeutics.
